BioSpace News Archive

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced it plans to develop TNX-102 SL as a potential treatment for Long COVID Syndrome which is now known officially as Post-Acute Sequelae of COVID-19.

Anavex Life Sciences Corp. reported predictive biomarker of response established with SIGMAR1 mRNA expression correlates significantly with responses in primary clinical efficacy endpoints from the U.S. Phase 2 randomized, double-blind, placebo-controlled trial of ANAVEX®2-73 in adult female patients with Rett syndrome.

Enochian BioSciences, Inc. announced that the company has acquired an exclusive license for an innovative technology to potentially treat and prevent all variants of coronavirus, including the cause of COVID-19, as well as influenza.

IBI-Ag, a biotechnology company developing a new class of bioinsecticides, announced an investment round for the optimization of its first product and expansion of the product portfolio spectrum.

Sierra Oncology, Inc., a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, announced the completion of enrollment for its pivotal Phase 3 MOMENTUM clinical trial evaluating the novel JAK1, JAK2 and ACVR1 / ALK2 inhibitor momelotinib in myelofibrosis patients who are symptomatic and anemic.

RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100 TM in advanced clinical development to treat severe COVID-19 patients, announces that all agenda items of yesterday’s Annual General Meeting were approved by a large majority of the represented votes.

The growth rate of the global surgical cutting devices market has increased tremendously over the past few years.

Even in crisis situations, such as war and earthquake trucks, trailers, trains, aircraft and ships that provide medical attention to people in need, mobile hospital can be moved into any part of the world.

According to the report, the global gallium-68 market was valued at ~US$ 100 Mn in 2020. It is projected to expand at a CAGR of ~8% from 2021 to 2031.

As per a study by Fact.MR, the global brain implant market is estimated to reach a valuation of US$ 9.2 billion by 2031.